Financial Information

Income Statement

v3.8.0.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Income Statement [Abstract]        
Net Sales $ 2,051,734 $ 1,384,429 $ 3,583,614 $ 4,252,704
Cost of Sales 535,572 388,202 1,068,174 1,268,320
Gross Profit 1,516,162 996,227 2,515,440 2,984,384
Operating expenses        
Compensation and related expenses 529,361 361,829 1,131,805 1,077,340
Professional fees 99,964 82,608 321,548 277,282
Marketing expenses 882,845 554,536 1,182,715 1,713,337
General and administrative expenses 277,559 204,958 753,402 382,857
Total operating expenses 1,789,729 1,203,931 3,389,470 3,450,816
Operating (Loss) (273,567) (207,704) (874,030) (466,432)
Change in fair value of derivative liability (377,213) 496,617
Interest (expense) (1,111) (9,992) (650,718) (15,805)
Net Income (Loss) (651,891) (217,696) (1,028,131) (482,237)
Net (loss) income attributable to noncontrolling interests 27,172 8,955 (41,752) 6,439
Net Income (loss) attributable to Immudyne, Inc. $ (679,063) $ (226,651) $ (986,379) $ (488,676)
Basic income (loss) per share attributable to Immudyne, Inc. $ (0.02) $ (0.01) $ (0.02) $ (0.02)
Diluted income (loss) per share attributable to Immudyne, Inc. $ (0.02) $ (0.01) $ (0.02) $ (0.02)
Average number of common shares outstanding        
Basic 44,160,477 34,427,087 40,888,131 31,917,873
Diluted 44,160,477 34,427,087 40,888,131 31,917,873

Source